Professor Mike Clarke
- Director of the Northern Ireland Clinical Trials Unit
- Northern Ireland Methodology Hub Lead, Queen’s University, Belfast
Professor Mike Clarke has nearly 30 years’ experience in the design and conduct of rigorous assessments of the effects of interventions through the use of randomised trials and systematic reviews. He joined CTSU in 1989 following a BA in chemistry and while finishing his DPhil on the history and epidemiology of suicide at the University of Oxford. Since then, he has been part of the Secretariat for the breast cancer overview, with a particular focus on the effects of ovarian ablation or suppression for women with early breast cancer. He was Director of the UK Cochrane Centre from 2002 to 2011 and now leads the Northern Ireland Methodology Hub at Queen’s University, Belfast and is Director of the Northern Ireland Clinical Trials Unit.
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) None., (2021), Lancet Oncol, 22, 1139 - 1150
Primary cam morphology; bump, burden or bog-standard? A concept analysis.
Dijkstra HP. et al, (2021), Br J Sports Med
Patient and Public Involvement in Research: A Journey to Co-Production
Price A. et al, (2021), Patient Education and Counseling
Compression stockings for preventing deep vein thrombosis in airline passengers.
Clarke MJ. et al, (2021), Cochrane Database Syst Rev, 4
Opinion and practice survey about the use of prognostic models in acute pulmonary embolism.
Elias A. et al, (2020), Thromb Res, 198, 40 - 48